Watson announced that the FDA has approved its Abbreviated New Drug Application (ANDA) for Trospium Chloride Extended-Release Capsules, the generic version of Allergan‘s Sanctura XR.

Sanctura XR is an antispasmodic indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. It lowers intravesicular pressure, increases capacity, and reduces the frequency of bladder contractions.

Trospium Chloride will be available in 60mg extended-release capsules. Watson intends to begin shipping the product immediately.

For more information call (800) 272-5525 or visit www.watson.com.